Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNC1 | P63316 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011336 | 1.00 | TNNC1 (0.51) | TNNC1FAAHTRPV1KCNH2TSHR | |
| SCHEMBL711621 | 0.92 | ALDH1A1 (0.44) | TNNC1FAAHTRPV1KCNH2TSHR | |
| SCHEMBL711622 | 0.92 | ALDH1A1 (0.44) | TNNC1FAAHTRPV1KCNH2TSHR | |
| SCHEMBL6046924 | 0.88 | TNNC1 (0.55) | TNNC1FAAHTRPV1KCNH2TSHR | |
| SCHEMBL8498180 | 0.83 | FAAH (0.43) | TNNC1FAAHTRPV1TSHR | |
| SCHEMBL8498184 | 0.83 | FAAH (0.43) | TNNC1FAAHTRPV1TSHR | |
| SCHEMBL10861866 | 0.82 | HDAC1 (0.46) | TNNC1FAAHTRPV1TSHRALDH1A1 | |
| SCHEMBL10861862 | 0.82 | HDAC1 (0.46) | TNNC1FAAHTRPV1TSHRALDH1A1 | |
| SCHEMBL1001650 | 0.81 | TNNC1 (0.55) | TNNC1TRPV1ALDH1A1 | |
| SCHEMBL1277033 | 0.81 | TNNC1 (0.55) | TNNC1TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960571-B2 | Silicon-based cross-coupling reagent and production method of organic compound using the same | KYOTO UNIVERSITY (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090069577-A1 | Silicon-Based Cross-Coupling Reagent and Production Method of Organic Compound Using the Same | KYOTO UNIVERSITY (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-0412803-B1 | Chalcone derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1994-03-23 | — | — | EP | disclosed |
| US-5089654-A | Antiulcer agents | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1992-02-18 | — | — | US | disclosed |
| EP-0412803-A1 | Chalcone derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069577-A1 | Silicon-Based Cross-Coupling Reagent and Production Method of Organic Compound Using the Same | DNMT1, TET3, CTCF | TNNC1 3618/4885FAAH 3904/4885TRPV1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.